Anti-herpes simplex virus activities of sulfomannan oligosaccharide PI-88 and disulfated cyclitols by Ekblad, Maria
Anti-herpes simplex virus activities of sulfomannan oligosaccharide 
PI-88 and disulfated cyclitols 
 
Maria Ekblad 
Department of Clinical Virology, Göteborg University 
 
Abstract 
 
     Herpes simplex virus (HSV) initiates invasion of human cells by binding to the cell surface 
heparan sulfate (HS) glycosaminoglycan chains. This step is mediated by the viral envelope 
glycoproteins gC and/or gB. Sulfated polysaccharides are compounds that mimic the structure 
of HS chains, and therefore are capable of inhibiting HSV attachment to and subsequent 
infection of cells. However the high molecular weight and associated with it poor tissue-
penetrating activity have limited potential antiviral application of sulfated polysaccharides in 
humans. Here we found that the HS mimetic PI-88, a sulfomannan oligosaccharide of low 
molecular weight, efficiently reduced, in contrast to conventional sulfated polysaccharides, 
the cell-to-cell spread of HSV. Analogues of PI-88 with chemical modifications based on the 
introduction of specific hydrophobic/aromatic group(s) at the reducing end of PI-88 
oligosaccharide chain showed enhanced capability to inhibit infection of cells and the cell-to-
cell transmission of HSV and respiratory syncytial virus (RSV). One of these analogues 
(denoted 536), prepared by modification of PI-88 with cholestanol group, exhibited in 
contrast to the parental compound an HSV-inactivating activity. Furthermore, several 
disulfated cyclitols, identified by screening for an anti-HSV activity of a large number of low 
molecular weight sulfated compounds, efficiently reduced the cell-to-cell spread of HSV and 
demonstrated an HSV-inactivating activity.  
     The second aim of this thesis was to elucidate the molecular basis for viral resistance to PI-
88. Variants of HSV type 1 (HSV-1) and type 2 (HSV-2), selected for by virus propagation in 
cultured cells in the presence of PI-88 were analysed. Many of these variants had a low 
infectious titer, indicative of a profound impairment in biological activities of the virus in 
response to continuous pressure from the drug. These variants were substantially resistant to 
PI-88 presence during their initial infection of cells and/or their cell-to-cell spread. Nucleotide 
sequence analysis revealed that PI-88 targeted predominantly the viral envelope glycoproteins 
that comprise mucin-like region(s), i.e., glycoprotein gC of HSV-1 and glycoprotein gG of 
HSV-2. The deletion of the mucin-like region of HSV-1 gC (amino acids 33-116) or the 
deletion of whole HSV-2 gG provided the virus with selective advantage to attach to and to 
infect cells in the presence of PI-88.  
     In conclusion, we have identified several novel antiviral compounds. One of these 
compounds, the PI-88 analogue 536, seems to be an attractive candidate for the development 
of a topical virucide for prevention of genital HSV infections in humans. We have also 
identified a novel biological function of HSV-2 gG, i.e., its targeting by sulfated 
oligosaccharides, which suggests involvement of this protein in HSV-2 attachment to cells or 
in modulation of this step. 
 
Keywords: herpes simplex virus, antiviral drugs, viral glycoproteins, 
heparan sulfate mimetic, PI-88 
 
ISBN:  978-91-628-7176-5 
Anti-herpes simplex virus activities of sulfomannan oligosaccharide 
PI-88 and disulfated cyclitols 
 
Akademisk avhandling 
 
som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin vid 
 Göteborgs universitet kommer att offentligen försvaras i  
Mikrobiologens föreläsningssal, Guldhedsgatan 10A, Göteborg, 
 
fredagen den 8 juni 2007 kl 09.00 
av 
 
Maria Ekblad 
 
Fakultetsopponent: 
Professor Tore Jarl Gutteberg, University of Tromsø, Tromsø, Norge  
 
Avhandlingen baseras på följande delarbeten: 
 
I. Nyberg K, Ekblad M, Bergström T, Freeman C, Parish CR, Ferro V, Trybala 
E. The low molecular weight heparan sulfate mimetic, PI-88, inhibits cell-to-cell 
spread of herpes simplex virus. Antiviral Research, 2004, 63:15-24.  
 
II. Ekblad M, Adamiak B, Bergefall K, Nenonen H, Roth A, Bergström T, Ferro 
V, Trybala E. Molecular basis for resistance of herpes simplex virus type 1 
mutants to the sulfated oligosaccharide inhibitor PI-88. Virology, in revision. 
 
III. Adamiak B, Ekblad M, Bergström T, Ferro V, Trybala E. Analysis of herpes 
simplex virus type 2 variants resistant to the sulfated oligosaccharide inhibitor PI-
88 identifies viral glycoprotein G as the major target of drug activity. In 
manuscript. 
 
IV. Ekblad M, Bergström T, Banwell MG, Bonnet M, Renner J, Ferro V, Trybala 
E. Anti-herpes simplex virus activities of two novel disulphated cyclitols. 
Antiviral Chemistry and Chemotherapy, 2006, 17:97-106. 
 
V. Ekblad M, Andrighetti-Fröhner CR, Bergström T, Banwell MG, Renner J, 
Kreipl A, Ferro V, Trybala E. Analogues of sulfated oligosaccharide PI-88 and 
disulfated cyclitol DSC3 exhibit potent anti-herpes simplex virus and anti-
respiratory syncytial virus activities. In manuscript. 
 
